420 related articles for article (PubMed ID: 21330577)
21. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
22. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients.
Cai MY; Hou JH; Rao HL; Luo RZ; Li M; Pei XQ; Lin MC; Guan XY; Kung HF; Zeng YX; Xie D
Mol Med; 2011; 17(1-2):12-20. PubMed ID: 20844838
[TBL] [Abstract][Full Text] [Related]
23. Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas.
Wang XY; Degos F; Dubois S; Tessiore S; Allegretta M; Guttmann RD; Jothy S; Belghiti J; Bedossa P; Paradis V
Hum Pathol; 2006 Nov; 37(11):1435-41. PubMed ID: 16949914
[TBL] [Abstract][Full Text] [Related]
24. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
25. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
[TBL] [Abstract][Full Text] [Related]
26. Enhancer of zeste homologue 2 (EZH2) is a reliable immunohistochemical marker to differentiate malignant and benign hepatic tumors.
Hajósi-Kalcakosz S; Dezső K; Bugyik E; Bödör C; Paku S; Pávai Z; Halász J; Schlachter K; Schaff Z; Nagy P
Diagn Pathol; 2012 Jul; 7():86. PubMed ID: 22809481
[TBL] [Abstract][Full Text] [Related]
27. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
28. Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.
Lee MH; Kim SH; Park MJ; Park CK; Rhim H
AJR Am J Roentgenol; 2011 Nov; 197(5):W868-75. PubMed ID: 22021534
[TBL] [Abstract][Full Text] [Related]
29. Improving pathological early diagnosis and differential biomarker value for hepatocellular carcinoma via RNAscope technology.
Bakheet AMH; Zhao C; Chen JN; Zhang JY; Huang JT; Du Y; Gong LP; Bi YH; Shao CK
Hepatol Int; 2020 Jan; 14(1):96-104. PubMed ID: 31832976
[TBL] [Abstract][Full Text] [Related]
30. The functional and mechanistic relatedness of EZH2 and menin in hepatocellular carcinoma.
Gao SB; Xu B; Ding LH; Zheng QL; Zhang L; Zheng QF; Li SH; Feng ZJ; Wei J; Yin ZY; Hua X; Jin GH
J Hepatol; 2014 Oct; 61(4):832-9. PubMed ID: 24845612
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.
Di Tommaso L; Franchi G; Park YN; Fiamengo B; Destro A; Morenghi E; Montorsi M; Torzilli G; Tommasini M; Terracciano L; Tornillo L; Vecchione R; Roncalli M
Hepatology; 2007 Mar; 45(3):725-34. PubMed ID: 17326147
[TBL] [Abstract][Full Text] [Related]
32. Distinct expression of polycomb group proteins EZH2 and BMI1 in hepatocellular carcinoma.
Yonemitsu Y; Imazeki F; Chiba T; Fukai K; Nagai Y; Miyagi S; Arai M; Aoki R; Miyazaki M; Nakatani Y; Iwama A; Yokosuka O
Hum Pathol; 2009 Sep; 40(9):1304-11. PubMed ID: 19386347
[TBL] [Abstract][Full Text] [Related]
33. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum.
Shafizadeh N; Ferrell LD; Kakar S
Mod Pathol; 2008 Aug; 21(8):1011-8. PubMed ID: 18536657
[TBL] [Abstract][Full Text] [Related]
34. Differentiation of well-differentiated hepatocellular carcinomas from other hepatocellular nodules in cirrhotic liver: value of SPIO-enhanced MR imaging at 3.0 Tesla.
Park HS; Lee JM; Kim SH; Chang S; Kim SJ; Han JK; Choi BI
J Magn Reson Imaging; 2009 Feb; 29(2):328-35. PubMed ID: 19161184
[TBL] [Abstract][Full Text] [Related]
35. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract][Full Text] [Related]
36. Glypican-3 immunocytochemistry in liver fine-needle aspirates : a novel stain to assist in the differentiation of benign and malignant liver lesions.
Kandil D; Leiman G; Allegretta M; Trotman W; Pantanowitz L; Goulart R; Evans M
Cancer; 2007 Oct; 111(5):316-22. PubMed ID: 17763368
[TBL] [Abstract][Full Text] [Related]
37. Fine needle aspiration biopsy of hepatocellular carcinoma and hepatocellular nodular lesions: role, controversies and approach to diagnosis.
Wee A
Cytopathology; 2011 Oct; 22(5):287-305. PubMed ID: 21762411
[TBL] [Abstract][Full Text] [Related]
38. High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas.
Kidani K; Osaki M; Tamura T; Yamaga K; Shomori K; Ryoke K; Ito H
Oral Oncol; 2009 Jan; 45(1):39-46. PubMed ID: 18619895
[TBL] [Abstract][Full Text] [Related]
39. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
Choi WT; Kakar S
Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
